Cervix carcinoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:19:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cervix carcinoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein https://clinicaltrials.eu/trial/study-of-bemarituzumab-treatment-for-patients-with-solid-tumors-that-have-high-levels-of-fgfr2b-protein/ Wed, 29 Apr 2026 15:07:15 +0000 https://clinicaltrials.eu/trial/study-of-bemarituzumab-treatment-for-patients-with-solid-tumors-that-have-high-levels-of-fgfr2b-protein/ This study focuses on various types of solid tumors that have a specific characteristic called FGFR2b overexpression. The types of cancer being studied include head and neck squamous cell carcinoma, triple-negative breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, ovarian epithelial carcinoma, endometrial adenocarcinoma, and cervical carcinoma. The treatment being tested is a medicine called bemarituzumab (also known as AMG 552), which is given through an intravenous infusion directly into the bloodstream.

The purpose of this research is to test how safe bemarituzumab is and how well it works in treating different types of solid tumors. The study is divided into two parts. In the first part, doctors will closely monitor how patients respond to the medication and any side effects that may occur. In the second part, they will evaluate how effective the medication is at fighting the cancer.

During the study, patients will receive bemarituzumab through regular infusions. The doctors will track the progress of the treatment using different medical tests and imaging scans such as computed tomography (CT) or magnetic resonance imaging (MRI). They will monitor how the tumors respond to the treatment and keep track of any changes in the patient’s health throughout the study period.

]]> Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-imgn151-for-women-with-recurrent-endometrial-and-ovarian-cancer/ Wed, 29 Apr 2026 15:00:46 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-imgn151-for-women-with-recurrent-endometrial-and-ovarian-cancer/ This clinical trial is focused on studying the safety and effectiveness of a new treatment called IMGN151 for women with certain types of cancer that have returned after treatment. The cancers being studied include recurrent endometrial cancer and recurrent high-grade serous epithelial ovarian cancer, as well as similar cancers affecting the lining of the abdomen and fallopian tubes. IMGN151 is a special type of medication known as an antibody-drug conjugate, which is designed to target and attack cancer cells more precisely.

The purpose of the study is to determine the best dose of IMGN151 that can be safely given to patients and to see how well it works in treating these cancers. The study will be conducted in two main phases. In the first phase, different doses of IMGN151 will be tested to find the safest and most effective dose. In the second phase, the chosen dose will be given to more patients to further assess its effectiveness. Throughout the study, participants will receive IMGN151 through an intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein.

Participants in the study will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to provide valuable information about the potential benefits and risks of IMGN151 for women with these specific types of recurrent cancers. This research is important for developing new treatment options that could improve outcomes for patients facing these challenging conditions.

]]>